Loading…
Jasper Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -99.3% over 5Y.
today you would have $5.94▼ -99.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $1.83 | $21.38 | $7.89 | $4.83 | $78.50 | $100.10 | |
| P/B | 4.3x | 12.3x | 5.2x | 1.1x | 0.5x | 4.3x | — |
| EPS | -$3.95 | -$4.89 | -$6.18 | -$10.33 | -$26.90 | -$51.70 | |
| ROE | -104.71% | -1826.09% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CNSYCerenome Inc | $3.05 | 1.1x | 4.1x | — | -614.05% | $23.15M |
| ENLVEnlivex Ltd. | $1.35 | 0.0x | 0.0x | — | 126.17% | $23.61M |
| BFRIBiofrontera Inc. | $1.59 | — | 3.8x | — | -988.35% | $23.62M |
| NXTCNextCure, Inc. | $5.18 |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Company description provided by Yahoo Finance.
| -115.56% |
| -82.18% |
| -104.71% |
| -44.07% |
| — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.7x |
| — |
| -204.56% |
| $23.71M |
| MRKRMarker Therapeutics, Inc. | $1.37 | — | 1.9x | — | -76.87% | $22.84M |
| CLRBCellectar Biosciences, Inc. | $2.53 | — | 0.7x | — | -119.57% | $23.91M |